HR Execs on the Move

Premier Incorporated

www.premierinc.com

 
As a leading national healthcare solutions organization, Premier, Inc. collaborates with healthcare organizations to improve supply chain management, decrease healthcare costs, integrate data and improve the health of communities. As an industry leader, Premier has created one of the most comprehensive database of actionable data, best practices and cost reduction strategies. We enable our members to collaborate easily and efficiently improve their quality outcomes, while reducing costs. By engaging members and revealing new opportunities, we empower our alliance to improve performance like no one else in healthcare can.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.premierinc.com
  • 13034 Ballantyne Corporate Place
    Charlotte, NC USA 28277
  • Phone: 704.357.0022

Executives

Name Title Contact Details
Amber Brannon
Senior Managed AP/CFO Advisor Profile
Patricia Sumrall
Director Supply Chain Management Profile
Bruce Radcliff
Senior Vice President of Supply Chain Services Profile
Myla Maloney
Chief Growth Officer, PINC AI Applied Profile
Melanie Proctor
Vice President, Supply Chain Data Profile

Similar Companies

Chicago Hospital Risk Pooling Program

Chicago Hospital Risk Pooling Program is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

LifeWise Health Plan of Oregon

LifeWise Health Plan of Oregon is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Finley Hospital

The Finley Hospital, a 142-bed facility, seeks to provide a continuum of care for all patients - newborn to geriatric.

Mr Grab Bar Inc

Mr Grab Bar Inc is a Naples, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.